S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
Log in

Haemonetics Stock Forecast, Price & News

-4.16 (-3.21 %)
(As of 03/2/2021 12:00 AM ET)
Today's Range
Now: $125.24
50-Day Range
MA: $127.75
52-Week Range
Now: $125.24
Volume572,180 shs
Average Volume379,030 shs
Market Capitalization$6.36 billion
P/E Ratio60.50
Dividend YieldN/A
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Haemonetics logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
Year FoundedN/A



Sales & Book Value

Annual Sales$988.48 million
Cash Flow$5.54 per share
Book Value$11.67 per share


Net Income$76.53 million


Market Cap$6.36 billion
Next Earnings Date5/4/2021 (Estimated)


Overall MarketRank

1.65 out of 5 stars

Medical Sector

277th out of 1,969 stocks

Surgical & Medical Instruments Industry

27th out of 169 stocks

Analyst Opinion: 2.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
-4.16 (-3.21 %)
(As of 03/2/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HAE News and Ratings via Email

Sign-up to receive the latest news and ratings for HAE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Haemonetics (NYSE:HAE) Frequently Asked Questions

Is Haemonetics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Haemonetics stock.
View analyst ratings for Haemonetics
or view top-rated stocks.

What stocks does MarketBeat like better than Haemonetics?

Wall Street analysts have given Haemonetics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Haemonetics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Haemonetics?

Haemonetics saw a increase in short interest in February. As of February 12th, there was short interest totaling 1,020,000 shares, an increase of 45.4% from the January 28th total of 701,400 shares. Based on an average daily trading volume, of 339,800 shares, the days-to-cover ratio is presently 3.0 days. Approximately 2.0% of the shares of the company are short sold.
View Haemonetics' Short Interest

When is Haemonetics' next earnings date?

Haemonetics is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Haemonetics

How were Haemonetics' earnings last quarter?

Haemonetics Co. (NYSE:HAE) announced its earnings results on Monday, February, 1st. The medical instruments supplier reported $0.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.65 by $0.16. The medical instruments supplier earned $240 million during the quarter, compared to the consensus estimate of $224.29 million. Haemonetics had a trailing twelve-month return on equity of 22.85% and a net margin of 11.76%. The firm's revenue was down 7.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.94 earnings per share.
View Haemonetics' earnings history

How has Haemonetics' stock been impacted by COVID-19?

Haemonetics' stock was trading at $103.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, HAE shares have increased by 20.7% and is now trading at $125.24.
View which stocks have been most impacted by COVID-19

What price target have analysts set for HAE?

5 brokerages have issued 1-year price objectives for Haemonetics' shares. Their forecasts range from $140.00 to $155.00. On average, they expect Haemonetics' stock price to reach $144.80 in the next twelve months. This suggests a possible upside of 15.6% from the stock's current price.
View analysts' price targets for Haemonetics
or view top-rated stocks among Wall Street analysts.

Who are Haemonetics' key executives?

Haemonetics' management team includes the following people:
  • Mr. Christopher A. Simon, CEO, Pres & Director (Age 57, Pay $2.53M)
  • Mr. William P. Burke, CFO & Exec. VP (Age 53, Pay $1.1M)
  • Ms. Michelle L. Basil, Exec. VP, Gen. Counsel & Sec. (Age 49, Pay $968.85k)
  • Ms. Jacqueline D. Scanlan, Sr. VP of HR (Age 48, Pay $792.1k)
  • Mr. Josep Lluis Llorens, Sr. VP of Global Manufacturing & Supply Chain (Age 59, Pay $826.89k)
  • Mr. Dan Goldstein, Principal Accounting Officer, VP & Corp. Controller (Age 44)
  • Ms. Anila Lingamneni, Exec. VP & Chief Technology Officer (Age 54)
  • Ms. Olga Guyette, Director of Investor Relations
  • Carla Burigatto, VP of Communications
  • Mr. Francis Tan, Sr. VP of Corp. Devel. & Planning

What is Christopher Simon's approval rating as Haemonetics' CEO?

48 employees have rated Haemonetics CEO Christopher Simon on Glassdoor.com. Christopher Simon has an approval rating of 63% among Haemonetics' employees. This puts Christopher Simon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Haemonetics' key competitors?

What other stocks do shareholders of Haemonetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), AbbVie (ABBV), Citigroup (C), Align Technology (ALGN), (APA), Chipotle Mexican Grill (CMG), Netflix (NFLX) and Pfizer (PFE).

What is Haemonetics' stock symbol?

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

Who are Haemonetics' major shareholders?

Haemonetics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.26%), Renaissance Technologies LLC (3.10%), Wells Fargo & Company MN (2.39%), Eaton Vance Management (1.88%), Morgan Stanley (1.37%) and Price T Rowe Associates Inc. MD (1.20%). Company insiders that own Haemonetics stock include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Mark W Kroll, Michelle L Basil, Richard J Meelia, Ronald G Gelbman, Said Bolorforosh and William P Mr Burke.
View institutional ownership trends for Haemonetics

Which institutional investors are selling Haemonetics stock?

HAE stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, BlackRock Inc., Eaton Vance Management, Jane Street Group LLC, Federated Hermes Inc., ExodusPoint Capital Management LP, Victory Capital Management Inc., and Morgan Stanley. Company insiders that have sold Haemonetics company stock in the last year include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Mark W Kroll, Michelle L Basil, Richard J Meelia, and William P Mr Burke.
View insider buying and selling activity for Haemonetics
or view top insider-selling stocks.

Which institutional investors are buying Haemonetics stock?

HAE stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Schroder Investment Management Group, Wells Fargo & Company MN, Thornburg Investment Management Inc., Nuveen Asset Management LLC, First Trust Advisors LP, Credit Suisse AG, and Beaconlight Capital LLC.
View insider buying and selling activity for Haemonetics
or or view top insider-buying stocks.

How do I buy shares of Haemonetics?

Shares of HAE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Haemonetics' stock price today?

One share of HAE stock can currently be purchased for approximately $125.24.

How much money does Haemonetics make?

Haemonetics has a market capitalization of $6.36 billion and generates $988.48 million in revenue each year. The medical instruments supplier earns $76.53 million in net income (profit) each year or $3.31 on an earnings per share basis.

How many employees does Haemonetics have?

Haemonetics employs 3,004 workers across the globe.

What is Haemonetics' official website?

The official website for Haemonetics is www.haemonetics.com.

Where are Haemonetics' headquarters?

Haemonetics is headquartered at 125 Summer Street, Boston MA, 02110.

How can I contact Haemonetics?

Haemonetics' mailing address is 125 Summer Street, Boston MA, 02110. The medical instruments supplier can be reached via phone at 781-848-7100 or via email at [email protected]

This page was last updated on 3/3/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.